MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7

Rhea-AI Summary

MyMD Pharmaceuticals announced the launch of two simultaneous Phase 2 trials for MYMD-1 this quarter, focusing on its ability to extend healthy lifespan and address COVID-19-associated depression. The trial results will be crucial for evaluating MYMD-1's potential as an immunometabolic regulator. The Company will also present its product pipeline at the Benzinga Rising Stars Conference on October 7, 2021, showcasing MYMD-1 and Supera-CBD, a synthetic CBD derivative targeting chronic pain and addiction.

Positive

• Launching two Phase 2 trials for MYMD-1 to study healthy lifespan extension and treatment of COVID-19-related depression.
• Presentation at the Benzinga Rising Stars Conference on October 7, 2021, to discuss the product pipeline.

Negative

• None.

MyMD to launch two simultaneous Phase 2 trials during the current quarter to study MYMD-1’s function in extending healthy lifespan and treating COVID-19-associated depression

BALTIMORE--(BUSINESS WIRE)-- MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. The Company’s presentation will be available for viewing that day at 10:10 a.m. ET on Benzinga’s live stream channel.

During the presentation, MyMD President, Director and Chief Medical Officer Chris Chapman, M.D. and Chief Scientific Officer Adam Kaplin, M.D., Ph.D. will discuss the Company’s product pipeline with diversified indications for MYMD-1 as an immunometabolic regulator and Supera-CBD as a synthetic CBD derivative.

About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.mymd.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed by MyMD on August 16, 2021. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005113/en/

Investor:

Robert Schatz

(646) 421-9523

rschatz@mymd.com

www.mymd.com

Media:

media@mymd.com

Source: MyMD Pharmaceuticals, Inc.

FAQ

What are the objectives of the Phase 2 trials for MYMD-1?

The Phase 2 trials aim to investigate MYMD-1's efficacy in extending healthy lifespan and treating COVID-19-associated depression.

When will MyMD present at the Benzinga Rising Stars Conference?

MyMD will present at the Benzinga Rising Stars Conference on October 7, 2021, at 10:10 a.m. ET.

What is MYMD-1 and its intended use?

MYMD-1 is an immunometabolic regulator being developed to treat chronic inflammation, with applications in longevity and COVID-19-related conditions.

What does Supera-CBD target?

Supera-CBD is designed to treat chronic pain, addiction, and epilepsy, providing improvements over existing CBD products.